Severe drug-induced immune hemolytic anemia due to cefmetazole: A case report
| Autor: | Osamu Takasu, Masafumi Fukuda, Shuki Oya, Masakazu Nabeta |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Anemia
Hemolytic Anemia medicine.medical_treatment Cefmetazole law.invention Immune Hemolytic Anemia law Humans Medicine Pharmacology (medical) Renal replacement therapy Aged 80 and over Pharmacology business.industry medicine.disease Intensive care unit Discontinuation Pharmaceutical Preparations Anesthesia Lactic acidosis Female Anemia Hemolytic Autoimmune Autoimmune hemolytic anemia business medicine.drug |
| Zdroj: | Int. Journal of Clinical Pharmacology and Therapeutics. 60:52-56 |
| ISSN: | 0946-1965 |
| DOI: | 10.5414/cp204095 |
| Popis: | Objective To report a case of drug-induced immune hemolytic anemia (DIIHA) that was suspected to have been caused by cefmetazole. Case summary A 93-year-old woman with no previous history of liver complications underwent a contrast-enhanced computed tomography scan, which resulted in a diagnosis of acute cholecystitis. The patient experienced intravascular hemolysis and rapid progression of anemia after being exposed to 2 g/day of cefmetazole. After 48 hours of cefmetazole administration, the patient was transferred to the intensive care unit (ICU) of our facility. In view of the severe autoimmune hemolytic anemia, the patient was started on steroid immunosuppression. The patient's condition further deteriorated for 13 hours after treatment and showed increased lactic acidosis and decreased consciousness, thus, the patient was intubated and managed on a ventilator. Lactic acidosis was not easily controlled, and the patient required continuous renal replacement therapy within 15 hours of ICU admission. Blood pressure was unable to be maintained even with the use of catecholamine, and the patient subsequently died 28 hours after ICU admission. Blood taken immediately after death was used to perform a drug-dependent antibody test where DIIHA due to cefmetazole was diagnosed. Conclusion If there is rapid progression of anemia following drug administration, the possibility of DIIHA needs to be considered. If DIIHA is suspected, identification and immediate discontinuation of the causal drug are essential, and a drug-dependent antibody test should be considered. . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|